2018 | Pharmaceutical Consulting, Regulatory Services, CEE

Kazakhstan Pharmaceutical and Medical Device Market Trends

export, Featured, UncategorizedBy wpusername9196 22. March 2018

NEWS REGULATORY CONSULTING PHARMACOVIGILANCE SERVICES MARKET ACCESS SERVICES MARKETING AND SALES Kazakhstan Pharmaceutical and Medical Device Market Trends In February 2018, the Bulgarian Drug Agency (BDA) announced new requirements for fee payments which are important for all applicants, marketing authorisation holders and their representatives. When requesting an administrative service for marketing authorization/registration, variations, renewals of…

Regarding medicinal products for which „sunset clause“ may already be applied

export, Featured, UncategorizedBy wpusername9196 19. March 2018

The State Medicines Control Agency on the ground of market monitoring data has compiled the list of medicinal products authorized in the Republic of Lithuania which more than for three years had not been supplied to the Lithuanian market. We here with remind that following Part 7 Article 14 of the Law on Pharmacy in…

Serbia – New Perspectives for Pharmaceuticals and Medical Devices

export, Featured, UncategorizedBy wpusername9196 5. March 2018

With Serbia making further progress with the EU accession process and the prospect of joining the EU in 2025, it is the country which gets increased attention of international pharmaceutical and medical device manufacturers.

Kazakh domestic pharmaceutical production up 79.8 percent in 2017

AllgemeinBy wpusername9196 1. March 2018

ASTANA – The Kazakh pharmaceutical industry increased production of the country’s most popular medications by 73.1 percent with production increasing 79.8 percent over 2016. Prices for pharmaceutical products in Kazakhstan have also increased 6.6 percent over the last 12 months.

Romania on the last place in EU for medical drugs consumption

AllgemeinBy wpusername9196 1. March 2018

NEWS REGULATORY CONSULTING PHARMACOVIGILANCE SERVICES MARKET ACCESS SERVICES MARKETING AND SALES Romania on the last place in EU for medical drugs consumption Romania is at the bottom of a European ranking regarding the consumption of medical drugs per capita, but not because they are healthier, but due to the precarious access to therapeutic solutions, according…

Falsified meds do not yet impose a serious threat in Hungary and the EU

AllgemeinBy wpusername9196 1. March 2018

“Due to strict regulations and legislatory monitoring no falsified or unauthorized medication has entered the legal drug supply chain in Hungary until now, stated the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM).

Overview of Estonian medicinal products market

AllgemeinBy wpusername9196 1. March 2018

NEWS REGULATORY CONSULTING PHARMACOVIGILANCE SERVICES MARKET ACCESS SERVICES MARKETING AND SALES Overview of Estonian medicinal products market Estonian annual drug statistics is based on wholesalers’ quarterly reports. The statistics of human medicinal products includes sales to general and hospital pharmacies and to other institutions, i.e. state and scientific institutions. WHOLESALERS In January 2018 there were…

Azerbaijan, Jordan may jointly produce pharmaceuticals

export, Featured, UncategorizedBy wpusername9196 26. February 2018

Azerbaijan offers Jordan to establish a joint pharmaceutical factory, Jordan Economy Ministry said on Feb. 21.

NATIONAL MEDICINES VERIFICATION ORGANISATIONS IN EASTERN EUROPE

export, Featured, UncategorizedBy wpusername9196 16. February 2018

To protect the EU pharmaceutical market from the entry of falsified medicines, the European Medicines Verification Organisation (EMVO) was created as a joint initiative of EU stakeholders, representing manufacturers, wholesalers and community pharmacists.

Slovakia’s amended tax laws may impact pharmaceutical sector

export, Featured, UncategorizedBy wpusername9196 13. February 2018

Slovakia’s approved Amendment to Act no. 595/2003 Coll. on Income Tax (ITA) and approved Amendment to Act no. 222/2004 Coll. on Value Added Tax (VATA), bring significant changes to the tax laws, effective 1 January 2018, which may affect pharmaceutical companies. The most relevant of these changes are:

Yearly Archives: 2018